Rhode Island is currently managing an atypical surge in COVID-19 infections, with viral levels in wastewater reaching some of the highest points recorded this year, according to data from the Rhode Island Department of Health. The current transmission rates are high, with the Pandemic Mitigation Collaborative estimating that 1 in every 24 people in the state is actively infectious.
This surge coincides with an early onset of influenza, with every part of the U.S. now showing high flu test positivity rates. The convergence of these two respiratory viruses has created a significant public health challenge, as COVID-19 and influenza are the only infectious diseases that regularly kill tens of thousands of Americans each year.
Rising Transmission Risks in Rhode Island
The viral activity in Rhode Island is concentrated in several areas, including Jamestown and the East Bay communities of Bristol, Warren, and Newport. Public health data indicates that if you are in a room with 10 people in the state, there is a 34% chance that at least one person is currently infectious with COVID-19.
The early arrival of the flu season is linked to mutations in the H1N1 virus, according to Maya Brownstein of the Harvard School of Public Health. This strain has developed the ability to evade existing immunity in some populations, particularly children and adolescents, who serve as major vectors of flu transmission. School-age children face a heightened danger of contracting the virus because they have only encountered the H1N1 strain linked to the 2009 flu pandemic and its descendants, whereas older populations possess immunity against a broader array of H1N1 variants.
Vaccination Options for COVID-19 and Influenza
Regulatory bodies have approved updated vaccines to match currently circulating variants. For COVID-19, the FDA has authorized four updated formulations:
- Comirnaty XFG (Pfizer): Approved for adults 65 and older and individuals ages 5 to 64 with underlying health conditions.
- Spikevax (Moderna): Available for those 65 and older, as well as individuals 6 months to 64 years old with underlying conditions.
- mNEXSPIKE (Moderna): Formulated to enhance activity in older adults, approved for ages 65 and up and those 12 to 64 with underlying conditions.
- Nuvaxovid (Sanofi): A non-mRNA option for adults 65 and older and those 12 to 64 at high risk for severe disease.
For influenza, the vaccine selection process is supported by mRNA technology in the form of the new mFlusiva vaccine. Evidence suggests that for patients 50 and older, mFlusiva may offer increased effectiveness compared to standard formulations. Other options include high-dose vaccines for seniors and nasal spray alternatives for individuals between the ages of 2 and 49.
Long-Term Health Impacts of Repeat Infections
Medical research indicates that COVID-19 continues to pose serious risks, with some studies suggesting the virus has not become milder over time. Research indicates that subsequent infections carry a 2 to 3 times higher likelihood of causing severe health consequences, including damage to organs, tissues, and systems, compared to the initial infection. Studies have also shown that most Long COVID cases started with initially mild infections.
Vaccine Matches Variants While Masks Reduce Viral Particle Inhalation
Does the current COVID-19 vaccine match the circulating variants?
Yes. Unlike in previous years where the virus evolved rapidly, there have been no significant new mutations observed beyond the strains that the current, FDA-approved vaccines are designed to target.
Why is it recommended to wear a mask if I am vaccinated?
Masking, particularly with an N95, KN95, or KF94 respirator, remains a highly effective method to reduce the inhalation of viral particles. Public health guidance suggests that wearing a mask in crowded, enclosed indoor spaces or during public transit significantly lowers the risk of infection, regardless of your vaccination status.
How does the new mRNA flu vaccine differ from traditional versions?
The mFlusiva vaccine uses mRNA technology, which allows for faster production compared to the traditional six-month manufacturing process. This speed enables a more rapid response if the influenza virus undergoes sudden mutations, potentially resulting in a better match for the circulating strain.